Galan Pilar, Briançon Serge, Favier Alain, Bertrais Sandrine, Preziosi Paul, Faure Henri, Arnaud Josiane, Arnault Nathalie, Czernichow Sébastien, Mennen Louise, Hercberg Serge
U557 Inserm ( UMR Inserm/Inra/CNAM), Institute Scientifique et Technique de la Nutrition et de l' Alimentation/CNAM, F-75003 Paris, France.
Br J Nutr. 2005 Jul;94(1):125-32. doi: 10.1079/bjn20051462.
The SUpplementation en VItamines et Mineraux AntioXydants (SU.VI.MAX) study, a randomised double-blind, primary-prevention trial showed that after 7.5 years, low-dose antioxidant supplementation lowered the total cancer incidence in men, but not in women. To explain this difference in the impact of antioxidant supplementation in men and women, we hypothesised that the effect of supplementation is dependent on initial antioxidant status; 12 741 French adults (7713 females aged 35--60 years; 5028 males aged 45--60 years) received daily antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg Se, 20 mg Zn daily) or a matching placebo. Cut-off limits for baseline serum concentrations of the different antioxidant vitamins and minerals were defined as follows for both men and women: 0.3 micromol/l for beta-carotene, 11.4 micromol/l for vitamin C, 15 micromol/l for vitamin E, 0.75 micromol/l for Se and 10.7 micromol/l for Zn. The percentage of men with serum concentrations under cut-off limits was higher for vitamins C and E and beta-carotene in those who developed a cancer than in those who did not. The risk of cancer was higher in men with baseline concentrations of serum vitamin C or vitamin E under cut-off limits, but not in women. The effect of supplementation was greater in men with baseline serum concentrations of vitamin C, vitamin E and beta-carotene below the cut-off limits compared with those above it. This effect was maintained only for vitamin E after adjustment for age, tobacco, and alcohol consumption and BMI. No effect of supplementation could be seen in women. Baseline antioxidant status is related to the risk of cancer in men but not in women and therefore does not entirely explain the differences observed in the effect of antioxidant supplementation on cancer risk between sexes in the SU.VI.MAX study.
抗氧化维生素和矿物质补充剂（SU.VI.MAX）研究是一项随机双盲初级预防试验，结果显示，7.5年后，低剂量抗氧化剂补充剂降低了男性的总体癌症发病率，但对女性没有效果。为了解释抗氧化剂补充剂对男性和女性影响的这种差异，我们假设补充剂的效果取决于初始抗氧化状态；12741名法国成年人（7713名35 - 60岁女性；5028名45 - 60岁男性）每天接受抗氧化剂补充剂（每日120毫克维生素C、30毫克维生素E、6毫克β-胡萝卜素、100微克硒、20毫克锌）或匹配的安慰剂。男性和女性不同抗氧化维生素和矿物质的基线血清浓度截断限值定义如下：β-胡萝卜素为0.3微摩尔/升，维生素C为11.4微摩尔/升，维生素E为15微摩尔/升，硒为0.75微摩尔/升，锌为10.7微摩尔/升。患癌者中维生素C、E和β-胡萝卜素血清浓度低于截断限值的男性比例高于未患癌者。基线血清维生素C或维生素E浓度低于截断限值的男性患癌风险较高，但女性并非如此。与基线血清维生素C、维生素E和β-胡萝卜素浓度高于截断限值的男性相比，低于截断限值的男性补充剂效果更大。在调整年龄、烟草、酒精消费和体重指数后，这种效果仅在维生素E方面得以维持。在女性中未观察到补充剂的效果。基线抗氧化状态与男性患癌风险相关，但与女性无关，因此不能完全解释在SU.VI.MAX研究中观察到的抗氧化剂补充剂对两性癌症风险影响的差异。
